Matches in SemOpenAlex for { <https://semopenalex.org/work/W2252622428> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2252622428 abstract "This study tested Perftoran blood substitute and Perftoran associated with NaCl 2.9% solution PSH for the use in hemorrhagic shock treatment in rats. For this study, 40 rats were divided into 4 groups: M (control), SH (hypertonic saline), P (Perftoran), PSH (Perftoran + hypertonic saline). Animals were anaesthetized, intubated and artificially ventilated with 100% oxygen. Carotid artery was catheterized for mean arterial pressure (MAP) measurement, blood withdraw, blood sampling and therapy administration. MAP and ECG lead II were recorded on a computer using Digidata 1200 acquisition system and AxoScope 10 acquisition software.A 10 minutes stabilization period was allowed prior to baseline values recording. Baseline values were recorded for a period of 20 minutes. After this period animals were partial exsanguinated by withdrawal of blood until MAP fall below 45 mmHg. Animals were maintained with MAP bellow 45 mmHg for 30 minutes, allowing hemorrhagic shock to install. Resuscitation was made after this period and values were recorded during a 30 minutes period after resuscitation. Primary resuscitation consisted in intra-arterial infusion of 5.25 ± 0.23 mL/100g NaCl 0.9% solution in group M, 2.75 ± 0.24 mL/100g NaCl 3.5% (HSS 3.5%) solution in group SH, 3.33 ± 0.28 mL/100g Perftoran emulsion in group P and 3.50 ± 0.35 mL/100g Perftoran + NaCl 2.9% association (called PSH) in group PSH.Heart rate increased after hemorrhagic shock in all groups and remained increased after therapy. No significant amelioration of heart rate is observed after therapy with 0.9% and 3.5% NaCl solution, Perftoran or PSH.MAP decreased to 41 mmHg in hemorrhagic shock in all groups. Afer therapy Perftoran and PSH increased MAP with 36.29% and respectively 29.79% compared to shock values. The MAP increase recorded after NaCl 0.9% and 3.5% administration was 15.26% and 15.48%. Results obtained show that Perftoran and Perftoran – NaCl 2.9% solution association increases MAP values to almost normal values. Due to the fact that therapy administration was made via I.A. way, we assume that the MAP increase will be greater if therapy is administrated via I.V. way and 7.5% NaCl solution is used.MAP increase after Perftoran administration was greater than after PSH administration probably due to an decrease of Perftoran dose. SSH 3.5% has little effect on MAP increase after hemorrhagic shock." @default.
- W2252622428 created "2016-06-24" @default.
- W2252622428 creator A5011386859 @default.
- W2252622428 creator A5075258692 @default.
- W2252622428 creator A5089618437 @default.
- W2252622428 date "2008-11-21" @default.
- W2252622428 modified "2023-09-27" @default.
- W2252622428 title "HEMODYNAMIC PARAMETERS AFTER PERFTORAN-HSS ADMINISTRATION" @default.
- W2252622428 doi "https://doi.org/10.15835/buasvmcn-vm:65:2:1503" @default.
- W2252622428 hasPublicationYear "2008" @default.
- W2252622428 type Work @default.
- W2252622428 sameAs 2252622428 @default.
- W2252622428 citedByCount "0" @default.
- W2252622428 crossrefType "journal-article" @default.
- W2252622428 hasAuthorship W2252622428A5011386859 @default.
- W2252622428 hasAuthorship W2252622428A5075258692 @default.
- W2252622428 hasAuthorship W2252622428A5089618437 @default.
- W2252622428 hasConcept C117277713 @default.
- W2252622428 hasConcept C126322002 @default.
- W2252622428 hasConcept C178853913 @default.
- W2252622428 hasConcept C2776452961 @default.
- W2252622428 hasConcept C2777397205 @default.
- W2252622428 hasConcept C2777953023 @default.
- W2252622428 hasConcept C2778165595 @default.
- W2252622428 hasConcept C2781300812 @default.
- W2252622428 hasConcept C3017567848 @default.
- W2252622428 hasConcept C42219234 @default.
- W2252622428 hasConcept C71924100 @default.
- W2252622428 hasConcept C84393581 @default.
- W2252622428 hasConceptScore W2252622428C117277713 @default.
- W2252622428 hasConceptScore W2252622428C126322002 @default.
- W2252622428 hasConceptScore W2252622428C178853913 @default.
- W2252622428 hasConceptScore W2252622428C2776452961 @default.
- W2252622428 hasConceptScore W2252622428C2777397205 @default.
- W2252622428 hasConceptScore W2252622428C2777953023 @default.
- W2252622428 hasConceptScore W2252622428C2778165595 @default.
- W2252622428 hasConceptScore W2252622428C2781300812 @default.
- W2252622428 hasConceptScore W2252622428C3017567848 @default.
- W2252622428 hasConceptScore W2252622428C42219234 @default.
- W2252622428 hasConceptScore W2252622428C71924100 @default.
- W2252622428 hasConceptScore W2252622428C84393581 @default.
- W2252622428 hasIssue "2" @default.
- W2252622428 hasLocation W22526224281 @default.
- W2252622428 hasOpenAccess W2252622428 @default.
- W2252622428 hasPrimaryLocation W22526224281 @default.
- W2252622428 hasRelatedWork W132019256 @default.
- W2252622428 hasRelatedWork W1967613775 @default.
- W2252622428 hasRelatedWork W1991588210 @default.
- W2252622428 hasRelatedWork W2024154703 @default.
- W2252622428 hasRelatedWork W2088117829 @default.
- W2252622428 hasRelatedWork W2112042775 @default.
- W2252622428 hasRelatedWork W2263749059 @default.
- W2252622428 hasRelatedWork W2312664291 @default.
- W2252622428 hasRelatedWork W2364910972 @default.
- W2252622428 hasRelatedWork W2412168598 @default.
- W2252622428 hasRelatedWork W2417453830 @default.
- W2252622428 hasRelatedWork W2419636395 @default.
- W2252622428 hasRelatedWork W2809654349 @default.
- W2252622428 hasRelatedWork W2884701785 @default.
- W2252622428 hasRelatedWork W2906510552 @default.
- W2252622428 hasRelatedWork W3000551873 @default.
- W2252622428 hasRelatedWork W3029454457 @default.
- W2252622428 hasRelatedWork W3029623776 @default.
- W2252622428 hasRelatedWork W3029809254 @default.
- W2252622428 hasRelatedWork W3032662442 @default.
- W2252622428 hasVolume "65" @default.
- W2252622428 isParatext "false" @default.
- W2252622428 isRetracted "false" @default.
- W2252622428 magId "2252622428" @default.
- W2252622428 workType "article" @default.